--Alliance designed to foster best in class cell therapy product and manufacturing innovation through risk-sharing and royalty-based model
Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance...
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.
/PRNewswire/ -- Former Attorney General of , , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). ...
--CALD is a rare neurodegenerative disease that can lead to progressive, irreversible loss of neurologic function, and death
Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.
--Company has informed EMA of lift of voluntary temporary marketing suspension
Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.
Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.
Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc....
Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.
--Across Phase 3 studies, 89% (32/36) of evaluable patients across ages and genotypes achieved TI and remain transfusion free, including 91% (20/22) of evaluable pediatric patients under the age of 18
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET.
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for...
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 50,000 shares of...
--As of the data cutoff date, 90% of patients (27/30) treated with SKYSONA in the pivotal ALD-102 clinical study met the primary endpoint of major functional disability (MFD)-free survival at two years...